Biotechnology landscape in cancer drug discovery
- PMID: 28031887
- PMCID: PMC5137916
- DOI: 10.4155/fso.15.10
Biotechnology landscape in cancer drug discovery
Keywords: cancer; drug discovery; hits and leads; immune-therapy; microRNA-based technology; next-generation sequencing; signaling pathway arrays; stem cells; technology optimization.
Conflict of interest statement
Financial & competing interests disclosure This work was partially supported by Grants PN 09.33–04.15, PN 09.33–03.10 and PN 09.33–01.01. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
References
-
- Raghu R, Devaraji V, Leena K, et al. Virtual screening and discovery of novel aurora kinase inhibitors. Curr. Top. Med. Chem. 2014;14(17):2006–2019. - PubMed
-
- Lacombe D, Tejpar S, Salgado R, et al. European perspective for effective cancer drug development. Nat. Rev. Clin. Oncol. 2014;11(8):492–498. - PubMed
-
- Yarden Y, Caldas C. Basic cancer research is essential for the success of personalised medicine. Eur. J. Cancer. 2013;49(12):2619–2620. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources